MedTrace Logo

Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV

NCT02590094 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 568

Last updated 2021-12-03

No results posted yet for this study

Summary

To compare outcomes in subjects receiving different doses and treatment intervals of intravitreal bevacizumab or ziv-aflibercept preoperatively administered prior to undergoing vitrectomy for complications of proliferative diabetic retinopathy.

Conditions

Interventions

DRUG

Intravitreal bevacizumab or intravitreal ziv-aflibercept

Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.

Sponsors & Collaborators

  • Panhandle Eye Group, LLP

    lead OTHER

Principal Investigators

  • Sloan Rush, MD · panhandle eye group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2019-01-04
Completion
2019-01-04

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02590094 on ClinicalTrials.gov